Little Green Pharma Ltd. · ASX:LGP
Little Green Pharma — Investor Presentation (June 2022)
23 slides from Little Green Pharma's investor presentation, Jun 6, 2022
Slide 1: Company Update
Company Update For personal use only ASX:LGP 3 June 2022 Our vision is to reimagine cannabis medicines and do extraordinary things for our patients. Our purpose is to solve real patient problems. A world of difference
Slide 2: Disclaimer
Disclaimer For personal use only Disclaimer Not financial product advice This presentation contains summary information about Little Green Pharma Ltd (ACN 615 586 This document does not constitute financial product advice or take into account your 215) (“LGP”) and its activities current as at the da
Slide 3: Corporate Overview
Corporate Overview For personal use only Capital Structure Register Breakdown6 Current Share Price1 $0.365 Shares Outstanding1 240,266,771 Institutional 37% Options and Performance Rights on Issue 12,940,536 Others Market Capitalisation (undiluted)1 ~$87.7 million 49% Cash Reserves (31 March 2022) ~
Slide 4: Investment Highlights
Investment Highlights LGP represents a market-leading, European and Oceania-focused medicinal cannabis offering for For personal use only investors seeking exposure to European and Oceania market opportunities • First company in Australia to both produce and export cannabis medicines Market leader i
Slide 5: Business Model
For personal use only Business Model
Slide 6: Our Business Model Captures Value
Our Business Model Captures Value LGP operates across the entire medicinal cannabis supply chain For personal use only Cultivation & Manufacturing Product Patient Access Sales & Production Innovation & Education Distribution EU GACP greenhouse EU-GMP recognised R&D pipeline includes QUEST Initiative
Slide 7: Growth Strategy
Growth Strategy Little Green Pharma has a track record of sales growth with a clear pathway to increasing margins For personal use only and driving significant revenue growth in Australia and offshore markets 1 2 3 4 Margin growth Patient acquisition Clear pathway to Product and drug and enhanced in
Slide 8: Market leader in Australia
For personal use only Market leader in Australia
Slide 9: Solid Sales Track Record
Solid Sales Track Record Strong growth in sales and patients using LGP products For personal use only REVENUE FY 20 $2.2m FY 21 $7.0m 9-month $10.5m FY20221 ACTIVE AUSTRALIAN NEW AUSTRALIAN CASH AT BANK PRESCRIBERS PATIENTS $40.2m 684 11,908 10,600 531 $20m 316 4,550 $4.2m FY 21 9-month FY 20 FY 21
Slide 10: QUality-of-life, Evaluation Study – sponsored by LGP
For personal use only QUality-of-life, Evaluation Study – sponsored by LGP An Australian project, the QUEST Initiative, is the world’s largest longitudinal study investigating the quality of life and health economics on patients with chronic disease who have been prescribed medicinal cannabis Total
Slide 11: World Class Cultivation & Manufacturing Capability
World Class For personal use only Cultivation & Manufacturing Capability
Slide 12: LGP Australia
LGP Australia For personal use only TGA-GMP manufacturing facility licensed to produce flower, extracts (oils), tinctures and APIs1 Indoor GACP cultivation facility capacity ~3 tonnes p.a. biomass Option to double cultivation capacity with further expansion if necessary 1. LGP also has a separate ex
Slide 13: LGP Denmark
LGP Denmark For personal use only World class cannabis cultivation and manufacturing facility GACP cultivation and EU-recognised GMP manufacturing Exports to Australia, Germany and Czech Republic Production capacity of >20 tonnes p.a. biomass • 21,500m2 glasshouse house cultivation area • 4,000m
Slide 14: LGP Denmark GMP certification of internal analytical laboratory facility
LGP Denmark Recent GMP certification of internal analytical laboratory facility For personal use only Analytical laboratory competitive advantage: • Currently no GMP certified cannabis testing laboratories in Denmark and very few laboratories across Europe • Testing laboratory moved to subsidiary fo
Slide 15: Dominant EU Distribution Platform Strategic Positioning
Dominant EU Distribution Platform For personal use only Strategic Positioning
Slide 16: Strategically Positioned in Europe
Strategically LGP has supply Positioned pathways across For personal use only Europe to access over in Europe 330m - 65% of the EU & UK population Currently Selling In DANISH FACILITY Strategically Positioned ~$1b MRA with Denmark ~$6b ~$3b ~$8b EU/UK Population: 515m LGP Total Addressable 330m Popu
Slide 17: Clear Pathway to International Sales
Clear Pathway to International Sales LGP’s Total Addressable Market (TAM) is 330m people and $34b For personal use only Population TAM Competitive Landscape Australia LGP, 35+ Australia’s first producer and first exporter of medicinal cannabis products with premium brand since August 2018 25m A$1b
Slide 18: Strong Innovation and R&D Pipeline
Strong Innovation and R&D Pipeline For personal use only
Slide 19: Product Innovation
Product Innovation Solving real patient problems For personal use only LGP currently manufactures four LGP-branded cannabis flower medicines – Meet the market – three THC dominant strains and one CBD dominant strain product line expansion LGP has spent substantial time and resources developing 2
Slide 20: R&D Pipeline
R&D Pipeline INNOVATE DEVELOP LAUNCH REGISTRATION For personal use only • Identify key unmet • Patient focused drug design • Rapid path to market access • Market Authorisation patient needs • Optimisation • Launch new medicine in (TGA, EMA, FDA) • Sponsor the QUEST • Scale-up Australia (SAS B) & glo
Slide 21: Our ESG commitment
Our ESG commitment LGP solves societal and environmental challenges through core business activities For personal use only SIX DIMENSIONS OF IMPACT Economic vitality H Access and inclusion M Environmental sustainability L 0 Societal enablement Lifetime well-being Ethical capacity Source: Model based
Slide 22: News Flow – Making Solid Progress
News Flow – Making Solid Progress Significant commercial progress as LGP executes growth strategy For personal use only Ethics approval for the Global Quest Initiative Release of new products Offtake agreement with new German distribution partner Sale of Denmark testing laboratory First shipment of
Slide 23: Connect
Connect Danish-made EU-GMP cannabis medicines For personal use only PO Box 690, West Perth Western AUSTRALIA 6872 P: +61 8 6280 0050 E: info@littlegreenpharma.com.au W: littlegreenpharma.com facebook.com/littlegreenpharma linkedin.com/company/little-green-pharma Australian-made TGA-GMP cannabis medi
Little Green Pharma — Investor Presentation (June 2022) on 6ix